DSIP: Delta Sleep-Inducing Peptide
Last updated: March 2026
DSIP is a 9-amino acid neuropeptide first isolated from rabbit brain during induced sleep. It promotes slow-wave delta sleep — the deepest, most restorative phase — while modulating stress response, circadian rhythm, and potentially pain perception.
🧪 Buy DSIP at Swiss Chems →in Sequence
Discovered
(mcg)
📋 On this page
What Is DSIP?
A natural sleep-regulatory peptide that was accidentally discovered during sleep research nearly 50 years ago.
In 1977, Swiss scientists Schoenenberger and Monnier isolated a 9-amino acid peptide from the cerebral venous blood of rabbits during electrically induced slow-wave sleep. The sequence — Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — was named Delta Sleep-Inducing Peptide (DSIP) for its ability to promote deep delta-wave sleep patterns.
DSIP is a nonapeptide: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (molecular weight ~848 Da). It is naturally produced in the hypothalamus and found in circulation during sleep states.
DSIP specifically promotes Stage 3/4 slow-wave sleep (delta sleep) — the phase responsible for physical restoration, growth hormone release, memory consolidation, and immune function.
Endogenous DSIP is synthesized in the hypothalamus, the brain region that regulates circadian rhythm, body temperature, hunger, and the sleep-wake cycle.
DSIP has been identified in mammals, birds, and invertebrates — suggesting it is an evolutionarily conserved sleep-regulatory molecule with fundamental biological importance.
How DSIP Works
DSIP acts through multiple neurochemical pathways — not a single receptor mechanism — which explains its diverse effects on sleep, stress, and pain.
DSIP promotes slow-wave (0.5-4 Hz) EEG patterns during sleep. Delta waves are associated with the deepest non-REM sleep stage, when the body releases growth hormone and performs tissue repair.
DSIP appears to help entrain circadian rhythm and normalize disturbed sleep-wake cycles. It may influence suprachiasmatic nucleus activity — the brain's master clock.
DSIP modulates GABAergic transmission — the primary inhibitory neurotransmitter system. Unlike benzodiazepines, it enhances natural sleep architecture rather than forcing sedation.
DSIP interacts with endogenous opioid systems, which may explain its potential analgesic (pain-reducing) properties observed in some animal studies.
DSIP normalizes cortisol levels under stress conditions. Animal studies show it can prevent stress-induced pathology and improve resilience to acute stressors.
DSIP exhibits free radical scavenging activity in vitro. This may contribute to its neuroprotective potential, though human relevance remains to be established.
What the Research Shows
DSIP has been studied for nearly 50 years, but most data comes from animal models and small human observational studies.
Sleep Research
Other Research Areas
Typical DSIP Protocols
Common research protocols based on published studies and reported user experience. Not prescriptive medical advice.
Starting dose: Begin at 100 mcg to assess individual response. Some individuals are more sensitive to DSIP's effects. Increase to 200-300 mcg only if needed after 3-5 days.
Why cycle? While tolerance data is limited, cycling is generally recommended for peptides affecting neurological pathways. The 2-4 week on / 2 week off pattern is based on common practice, not clinical trials.
DSIP optimizes sleep architecture while Selank provides daytime anxiolytic support via GABA modulation. They work through different pathways and are commonly used together — DSIP for restorative sleep, Selank for calm, focused wakefulness.
Safety Considerations
DSIP appears well-tolerated in published studies, but long-term human safety data is limited.
Key Study Citations
Key Takeaways
- 9-amino acid neuropeptide discovered 1977
- Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
- Naturally produced in the hypothalamus
- Promotes slow-wave (delta) sleep — deepest sleep phase
- Interacts with GABA and opioid systems
- Stress-protective effects in animal models
- Potential antioxidant and analgesic properties
- Generally well-tolerated in available studies
- No large Phase 2/3 human clinical trials
- Precise receptor mechanism still debated
- Optimal dose for humans not established
- Long-term safety profile unknown
- Pharmacokinetics in humans poorly characterized
- Whether observed effects translate from animals to humans
- Interactions with other sleep/CNS compounds
🛒 Recommended Products
Sleep optimization and peptide research supplies.
Affiliate links help support HighPeptides at no extra cost to you.
🔗 Related Resources
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and informational purposes only. DSIP (Delta Sleep-Inducing Peptide) is a research peptide not approved by the FDA or any regulatory body for human therapeutic use. Most published research consists of animal studies and small human observational studies. No large human clinical trials have been completed. The safety and efficacy of DSIP in humans has not been established. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.